Open AccessA Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
Author(s) -
Chia Jui Yen,
Tae You Kim,
Feng Yin,
Yee Chao,
Lin Deng,
Baek Yeol Ryoo,
Dennis Huang,
David Schnell,
Julia Hocke,
Arsene-Bienvenu Loembé,
Ann Lii Cheng
Publication year - 2018
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000486460
Subject(s) - nintedanib , sorafenib , hepatocellular carcinoma , pharmacokinetics , medicine , oncology , phases of clinical research , pharmacology , clinical trial , lung , idiopathic pulmonary fibrosis
Nintedanib is an oral, triple angiokinase inhibitor of vascular endothelial growth factor/platelet-derived growth factor/fibroblast growth factor receptors. This randomized, multicenter, open-label, phase I/II study evaluated the safety, pharmacokinetics, maximum tolerated dose (MTD) in terms of dose-limiting toxicities (DLTs), and efficacy of nintedanib versus sorafenib in Asian patients with unresectable advanced hepatocellular carcinoma (HCC).